This multicenter, open-label, single arm long term extension of study WA19926 will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients with early, moderate to severe rheumatoid arthritis who have completed the WA19926 core study. Eligible patients will receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks for up to 104 weeks.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01665430?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
